Illumina received an emergency authorization from the FDA for its COVID-19 test designed to sequence the full genome of the novel coronavirus. Using the company’s high-throughput NovaSeq 6000 hardware ...
SAN DIEGO, June 7, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today shared key customer-focused announcements and presentations ...
MELBOURNE, Australia--(BUSINESS WIRE)--Illumina, Inc., the global leader in DNA sequencing and array-based technologies and Next Generation Genomic Co., Ltd. (NGG Thailand), the Association of ...
After a long wait, Illumina has revealed a new series of sequencing instruments—the NovaSeq X series, designed to cement its position as the leader in next-gen sequencing in the face of intense ...
SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) today announced it has expanded the world’s most comprehensive next-generation sequencing (NGS) portfolio with the launch of the HiSeq X Five ...
International Day of World’s Indigenous Peoples is celebrated each year on August 9. On this day, people from around the world are encouraged to spread the United Nation’s message on the protection ...
San Diego’s Illumina has won regulatory approval for the first COVID-19 test based on next- generation gene sequencing, which could help track mutations of the virus while delivering high-volume ...
Gene sequence giant Illumina is weighing its next moves after a federal jury in Delaware found the San Diego company infringed on two patents from a rival genomics company and awarded $334 million in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback